Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2248-2252

  Parquet, Véronique ^a   Briolant, Sébastien ^a   Torrentino Madamet, Marylin ^a   Henry, Maud ^a   Almeras, Lionel ^a   Amalvict, Rémy ^a   Baret, Eric ^a   Fusaï, Thierry ^a   Rogier, Christophe ^a   Pradines, Bruno ^a  

^a SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; ATORVASTATIN; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; DOXYCYCLINE; FLUINDOSTATIN; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN 1; PRAVASTATIN; QUININE; SIMVASTATIN;

ADJUVANT THERAPY; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; CROSS RESISTANCE; DEATH; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; GENE MUTATION; GROWTH INHIBITION; IN VITRO STUDY; MALARIA; MALARIA FALCIPARUM; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 67049107926     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01462-08     Document Type: Article

References (32)

1. + exchanger activity and quinine resistance. Mol. Biochem. Parasitol. 153:48-58.
2. Bienvenu, A. L., and S. Picot. 2008. Statins alone are ineneffective in cerebral malaria but potentiate artesunate. Antimicrob. Agents Chemother. 52:4203-4204.
3. Bogreau, H., F. Renaud, H. Bouchiba, P. Durand, S. B. Assi, M. C. Henry, E. Garnotel, B. Pradines, T. Fusai, B. Wade, E. Adehossi, P. Parola, M. A. Kamil, O. Puijalon, and C. Rogier. 2006. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am. J. Trop. Med. Hyg. 74:953-959.
4. Botelho-Nevers, E., L. Espinosa, D. Raoult, and J. M. Rolain. 2008. Lovastatin, but not pravastatin, limits in vitro infection due to Coxiella burnetii. J. Antimicrob. Chemother. 62:845-847.
5. Catron, D. M., Y. Lange, J. Borenztajn, M. D. Sylvester, B. D. Jones, and K. Haldar. 2004. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect. Immun. 72:1036-1042.
6. Combes, V., N. Coltel, D. Faille, S. C. Wassmer, and G. E. Grau. 2006. Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int. J. Parasitol. 36:541-546.
7. Coppens, I., P. Bastin, T. Levade, and P. J. Courtoy. 1995. Activity, pharmacological inhibition and biological regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase in Trypanosoma brucei. Mol. Biochem. Parasitol. 69:29-40.
8. Couto, A. S., E. A. Kimura, V. J. Peres, M. L. Uhrig, and A. M. Katzin. 1999. Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units. Biochem. J. 341:629-637.
9. Dokomajilar, C., S. L. Nsobya, B. Greenhouse, P. J. Rosenthal, and G. Dorsey. 2006. Selection of Plasmodium falciparum Pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 50:1893-1895.
10. Durrand, V., A. Berry, R. Sem, P. Glaziou, J. Beaudou, and T. Fandeur. 2004. Variations in the sequence and expression of the Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and their relationship to chloroquine resistance in vitro. Mol. Biochem. Parasitol. 136:273-285. (Pubitemid 38757996)
11. Falagas, M. E., G. C. Makris, D. K. Matthaiou, and P. I. Rafailidis. 2008. Statins for infection and sepsis: a systematic review of the clinical evidence. J. Antimicrob. Chemother. 61:774-785.
12. Ferdig, M. T., R. A. Cooper, J. Mu, B. Deng, D. A. Joy, X. Z. Su, and T. E. Wellems. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52:985-997.
13. Greenwood, J., and J. C. Mason. 2007. Statins and the vascular endothelial inflammatory response. Trends Immunol. 28:88-98. (Pubitemid 46178495)
14. Grellier, P., A. Valentin, V. Millerioux, J. Schrevel, and D. Rigomier. 1994. 3-Hydroxy-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes. Antimicrob. Agents Chemother. 38:1144-1148.
15. Henry, M., S. Alibert, C. Rogier, J. Barbe, and B. Pradines. 2008. Inhibition of efflux of quinolines as new therapeutic strategy in malaria. Curr. Top. Med. Chem. 8:563-578.
16. Henry, M., I. Diallo, J. Bordes, S. Ka, B. Pradines, B. Diatta, P. S. M'Baye, M. Sane, M. Thiam, P. M. Gueye, B. Wade, J. E. Touze, J. M. Debonne, C. Rogier, and T. Fusai. 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am. J. Trop. Med. Hyg. 75:146-151.
17. Hochman, J. H., N. Pudvah, J. Qiu, M. Yamasaki, C. Tang, J. H. Lin, and T. Prueksaritanont. 2004. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res. 21:1686-1691.
18. Kobbe, R., N. Schreiber, J. May, and T. Jacobs. 2008. Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria. Antimicrob. Agents Chemother. 52:1583-1584.
19. Lambros, C., and J. P. Vanderberg. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420.
20. Le Bras, J., L. Musset, and J. Clain. 2006. Antimalarial drug resistance. Med. Maladies Infect. 36:401-405.
21. Lopes, D., K. Rungsihirunrat, F. Nogueira, A. Seugorn, J. P. Gil, V. E. do Rosario, and P. Cravo. 2002. Molecular characterization of drug-resistant Plasmodium falciparum from Thailand. Malaria J. 1:12.
22. Mayer, J., T. Eller, P. Brauer, E. M. Solleder, R. M. Schäfer, F. Keller, and K. Kochsiek. 1992. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann. Hematol. 64:196-201.
23. Mu, J., M. T. Ferdig, X. Feng, D. A. Joy, J. Duan, T. Furuya, G. Subramanian, L. Aravind, R. A. Cooper, J. C. Wootton, M. Xiong, and X. Z. Su. 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49:977-989.
24. Naik, R. S., M. Venkatesan, and D. C. Gowda. 2001. Plasmodium falciparum: the lethal effects of tunicamycin and mevastatin on the parasite are not mediated by inhibition of N-linked oligosaccharide biosynthesis. Exp. Parasitol. 98:110-114.
25. Pradines, B., V. Parquet, and E. Orlandi-Pradines. 2008. ABC transporters in Plasmodium falciparum and their involvement in resistance to animalarial drugs. In A. Ponte-Sucre (ed.), ABC transporters in microorganisms, in press. Horizon Scientific Press, Norfolk, United Kingdom.
26. Pradines, B., M. Torrentino-Madamet, A. Fontaine, M. Henry, E. Baret, J. Mosnier, S. Briolant, T. Fusai, and C. Rogier. 2007. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob. Agents Chemother. 51:2654-2655.
27. Song, J. L., C. N. Lyons, S. Holleman, B. G. Oliver, and T. C. White. 2003. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med. Mycol. 41:417-425. (Pubitemid 37441445)
28. Terblanche, M., Y. Almog, R. S. Rosenson, T. S. Smith, and D. G. Hackam. 2006. Statins: panacea for sepsis? Lancet Infect. Dis. 6:242-248.
29. Ursing, J., P. E. Kofoed, A. Rodrigues, L. Rombo, and J. P. Gil. 2007. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am. J. Trop. Med. Hyg. 76:844-848.
30. Ursing, J., S. Zakeri, J. P. Gil, and A. Bjorkman. 2006. Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop. 97:352-356.
31. Wu, X., I. Whitfield, and B. H. Stewart. 2000. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. 17:209-215.
32. Yokoyama, K., P. Trobridge, F. S. Buckner, J. Scholten, K. D. Stuart, W. C. van Voorhis, and M. H. Gelb. 1998. The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol. Biochem. Parasitol. 94:87-97.